Different compositions of pharmaceuticals in Dutch and Belgian rivers explained by consumption patterns and treatment efficiency

Environmental Science and Pollution Research

Volumn 21, Issue 22, 2014, Pages 12843-12855

  ter Laak, Thomas L ^a,b   Kooij, Pascal J F ^a   Tolkamp, Harry ^a,c   Hofman, Jan ^a  

^a KWR WATERCYCLE RESEARCH INSTITUTE   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c Roer and Overmaas Regional Water Authority   (Netherlands)

Author keywords

Belgium; Consumption based modelling of emissions; Pharmaceuticals; Regional waters; Surface water; The Netherlands; Transformation products

Indexed keywords

GUANIDINE DERIVATIVE; METFORMIN; N-GUANYLUREA; UREA; WASTE WATER; WATER POLLUTANT;

ANALOGS AND DERIVATIVES; ANALYSIS; BELGIUM; CHEMISTRY; COMPARATIVE STUDY; DRUG UTILIZATION; HUMAN; NETHERLANDS; RIVER; WASTE WATER; WATER POLLUTANT; WATER QUALITY;

BELGIUM; DRUG UTILIZATION; GUANIDINES; HUMANS; METFORMIN; NETHERLANDS; RIVERS; UREA; WASTE WATER; WATER POLLUTANTS, CHEMICAL; WATER QUALITY;

EID: 84937965126     PISSN: 09441344     EISSN: 16147499     Source Type: Journal    
DOI: 10.1007/s11356-014-3233-9     Document Type: Article

References (52)

1. Alder AC, Schaffner C, Majewsky M, Klasmeier J, Fenner K (2010) Fate of β-blocker human pharmaceuticals in surface water: comparison of measured and simulated concentrations in the Glatt Valley Watershed, Switzerland. Water Res 44:936–948
2. Ardakani YH, Rouini RM (2009) Pharmacokinetic study of tramadol and its three metabolites in plasma, saliva and urine. DARU 17:245–255
3. Belgian Centre for Pharmacotherapeutic Information (Belgisch Centrum voor Farmacotherapeutische Informatie, BCFI) "Hypolipemiërende middelen" June 2014 (http://www.bcfi.be)
4. Boyjoo Y, Pareek VK, Ang M (2013) A review of greywater characteristics and treatment processes. Water Sci Technol 67:1403–1424
5. Carr RA, Foster RT, Lewanczuk RZ, Hamilton PG (1992) Pharmacokinetics of sotalol enantiomers in humans. J Clin Pharmacol 32:1105–1109
6. Castiglioni S, Fanelli R, Calamari D, Bagnati R, Zuccato E (2004) Methodological approaches for studying pharmaceuticals in the environment by comparing predicted and measured concentrations in River Po, Italy. Regul Toxicol Pharmacol 39:25–32
7. Castiglioni S, Bagnati R, Fanelli R, Pomati F, Calamari D, Zuccato E (2006) Removal of pharmaceuticals in sewage treatment plants in Italy. Environ Sci Technol 40:357–363
8. Chitil L, Sticha M, Matouskova O, Perlik F, Slanar O (2009) Enantiomeric determination of tramadol and O-desmethyltramadol in human urine by gas chromatography-mass spectrometry. J Chromatogr B 877:1937–1942
9. Clara M, Strenn B, Kreuzinger N (2004) Carbamazepine as a possible anthropogenic marker in the aquatic environment: investigations on the behaviour of Carbamazepine in wastewater treatment and during groundwater infiltration. Water Res 38:947–954
10. de Jongh CM, Kooij PJF, de Voogt P, ter Laak TL (2012) Screening and human health risk assessment of pharmaceuticals and their transformation products in Dutch surface waters and drinking water. Sci Total Environ 427–428:70–77
11. de Voogt P, Janex-Habibi M-L, Sacher F, Puijker LM, Mons M (2009) Development of a common priority list of pharmaceuticals relevant for the water cycle. Water Sci Technol 59:39–46
12. Directorate General Statistics and Economic Information (DGSEI) "Statistics Belgium" December 2013. (http://statbel.fgov.be/)
13. Dix KJ, Coleman DP, Jeffcoat AR (1999) Comparative metabolism and disposition of gemfibrozil in male and female Sprague-Dawley rats and Syrian golden hamsters. Drug Metab Dispos 27:138–146
14. Eichelbaum M, Tomson T, Tybring G, Bertilsson L (1985) Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet 10:80–90
15. Escher BI, Fenner K (2011) Recent advances in environmental risk assessment of transformation products. Environ Sci Technol 45:3835–3847
16. European Medicines Agency (1997) Trimethoprim. Summary Report (2). European Agency for the Evaluation of Medicinal Products, London, p 10
17. European Medicines Agency (1998) Lincomycin—summary report. European Medicines Agency, London, p 10
18. Grubb NG, Rudy DW, Brater DC, Hall SD (1999) Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. Br J Clin Pharmacol 48:494–500
19. Heberer T (2002) Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol Lett 131:5–17
20. Howell SR, Husbands GEM, Scatina JA, Sisenwine SF (1993) Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 23:349–359
21. Kugathas S, Williams RJ, Sumpter JP (2012) Prediction of environmental concentrations of glucocorticoids: the River Thames, UK, as an example. Environ Int 40:15–23
22. Lamp KC, Freeman CD, Klutman NE, Lacy MK (1999) Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36:353–373
23. Larsson DGJ, de Pedro C, Paxeus N (2007) Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater 148:751–755
24. Liebig M, Moltmann JF, Knacker T (2006) Evaluation of measured and predicted environmental concentrations of selected human pharmaceuticals and personal care products. Environ Sci Pollut Res 13:110–119
25. Lienert J, Gudel K, Escher BI (2007) Screening method for ecotoxicological hazard assessment of 42 pharmaceuticals considering human metabolism and excretory routes. Environ Sci Technol 41:4471–4478
26. Lintz W, Erlacin S, Frankus E, Uragg H (1981) Biotransformation of tramadol in man and animal. Metab Tramadol Mensch Tier 31:1932–1943
27. Mezcua M, Malato O, Garcia-Reyes JF, Molina-Diaz A, Fernandez-Alba AR (2009) Accurate-mass databases for comprehensive screening of pesticide residues in food by fast liquid chromatography time-of-flight mass spectrometry. Anal Chem 81:913–929
28. Miege C, Choubert JM, Ribeiro L, Coquery M (2009) Fate of pharmaceuticals and personal care products in wastewater treatment plants - conception of a database and first results. Environ Pollut 157:1721–1726
29. Monteiro SC, Boxall ABA (2010) Occurence and fate of human pharmaceuticals in the environment. Rev Environ Contam Toxicol 202:53–154
30. Mossialos E, Mrazek M, Walley T (2004) regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. WHO on behalf of the European Observatory on Health Systems and Policies, Cornwall, p 395
31. Onesios KM, Yu JT, Bouwer EJ (2009) Biodegradation and removal of pharmaceuticals and personal care products in treatment systems: a review. Biodegradation 20:441–466
32. Oosterhuis M, Sacher F, ter Laak TL (2013) Prediction of concentration levels of metformin and other high consumption pharmaceuticals in wastewater and regional surface water based on sales data. Sci Total Environ 442:380–388
33. Pomiès M, Choubert JM, Wisniewski C, Coquery M (2013) Modelling of micropollutant removal in biological wastewater treatments: a review. Sci Total Environ 443:733–748
34. Prescott LF (1980) Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol 10:291S–298S
35. Radjenovic J, Petrovic M, Barceló D (2007) Analysis of pharmaceuticals in wastewater and removal using a membrane bioreactor. Anal Bioanal Chem 387:1365–1377
36. RIWA Maas (2009) Stroomgebiedsbeheersplan voor het internationale district van de Maas - Overkoepelend deel. RIWA Maas, Liege
37. Roig B (2010) Pharmaceuticals in the environment - current knowledge and need assessment to reduce presence and impact. IWA, London, p 198
38. Rosal R, Rodriguez A, Perdigon-Melon JA, Petre A, Garcia-Calvo E, Gomez MJ, Aguera A, Fernandez-Alba AR (2010) Occurrence of emerging pollutants in urban wastewater and their removal through biological treatment followed by ozonation. Water Res 44:578–588
39. Rúa-Gómez PC, Püttmann W (2012) Occurrence and removal of lidocaine, tramadol, venlafaxine, and their metabolites in German wastewater treatment plants. Environ Sci Pollut Res 19:689–699
40. Scheurer M, Sacher F, Brauch H-J (2009) Occurence of the antidiabetic drug metformin in sewage and surface waters in Germany. J Environ Monit 11:1608–1613
41. Scheurer M, Michel A, Brauch HJ, Ruck W, Sacher F (2012) Occurrence and fate of the antidiabetic drug metformin and its metabolite guanylurea in the environment and during drinking water treatment. Water Res 46:4790–4802
42. SPGE (2006) PASH Plan dássainissement par sous-bassin hydrographique; sous-bassin de la Meuse Aval. Société Publique de Geistion de l'Eau
43. Sui Q, Huang J, Deng S, Chen W, Yu G (2011) Seasonal variation in the occurrence and removal of pharmaceuticals and personal care products in different biological wastewater treatment processes. Environ Sci Technol 45:3341–3348
44. ter Laak TL, Van der Aa M, Stoks P, Houtman C, van Wezel AP (2010) Relating environmental concentrations of pharmaceuticals to consumption: a mass balance approach for the river Rhine. Environ Int 36:403–409
45. Tu ZG, Zhao LL (1995) Metoprolol α-hydroxylation capacity in 96 Chinese Han volunteers. Acta Pharmacol Sin 16:325–329
46. van Batenburg-Eddes T, van den Berg-Jeths A, van der Veen AA, Verheij RA, de Neeling A (2002) Consumption in the Netherlands, regional variations in consumption of pharmaceuticals. "Slikken in Nederland. Regionale variaties in geneesmiddelengebruik". RIVM, Bilthoven, p 76
47. Van den Berg Jeths A, Van Batenburg-Eddes T (2003) The Netherlands swallows differently. Regional variations in cost and usage of medicines. Pharm Weekbl 138:840–844
48. Van Loenen AC (2008) Farmacotherapeutisch Kompas. CVZ
49. Vergouwen AA, Pieters BJ, Kools S (2011) Inventarisatie van emissie van geneesmiddelen uit zorginstellingen. ZORG, Deel C. STOWA, Amersfoort
50. Verlicchi P, Al Aukidy M, Zambello E (2012) Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment-a review. Sci Total Environ 429:123–155
51. Watkinson AJ, Murby EJ, Costanzo SD (2007) Removal of antibiotics in conventional and advanced wastewater treatment: implications for environmental discharge and wastewater recycling. Water Res 41:4164–4176
52. Wick A, Fink G, Joss A, Siegrist H, Ternes TA (2009) Fate of beta blockers and psycho-active drugs in conventional wastewater treatment. Water Res 43:1060–1074